Research outcomes from section 1 research with exidavnemab printed in The Journal of Medical Pharmacology By Investing.com

STOCKHOLM, Aug. 27, 2024 /PRNewswire/ — BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) introduced at the moment that the outcomes from two phase-1 research with exidavnemab have been printed in The Journal of Medical Pharmacology. Exidavnemab is a drug candidate underneath growth aimed toward treating ailments reminiscent of Parkinson’s illness. It’s a monoclonal antibody designed to focus on aggregated types of the protein α-synuclein, whereas sparing the physiological type of the protein.

In two separate section 1 scientific research carried out in collaboration with AbbVie (NYSE:), exidavnemab was examined on wholesome volunteers to evaluate the protection, tolerability and pharmacokinetics of the candidate drug. The research included 98 members from totally different ethnic backgrounds, of which 85 acquired exidavnemab, both as an intravenous dose starting from 100 to 6000 mg or a subcutaneous dose of 300 mg.

The outcomes confirmed that exidavnemab was usually well-tolerated. with a wonderful half-life of roughly 30 days. This along with the excessive affinity and selectivity towards the pathological aggregated types of α-synuclein is vital to take care of a excessive goal binding within the mind.

“Data from these two studies support the continued clinical development of exidavnemab, and we are looking forward to starting the phase 2a study later this year,” mentioned Gunilla Osswald, CEO of BioArctic, in a remark.

The printed article could be learn in full right here:  https://accp1.onlinelibrary.wiley.com/doi/10.1002/jcph.6103

This launch discusses investigational makes use of of an agent in growth and isn’t meant to convey conclusions about efficacy or security. There isn’t a assure that such investigational brokers will efficiently full scientific growth or acquire well being authority approval.

The knowledge was launched for public disclosure, by way of the company of the contact individual beneath, on August 27, 2024, at 08:00 a.m. CET.

For additional data, please contact:Oskar Bosson, Vice President Communications and Investor Relations
E-mail: oskar.bosson@bioarctic.se
Telephone: +46 70 410 71 80

Jiang Millington, Company Communication and Social Media Director
E-mail: jiang.millington@bioarctic.se
Telephone: +46 79 33 99 166

About Exidavnemab

Exidavnemab is a monoclonal antibody drug candidate that’s designed to selectively bind and get rid of aggregated types of alpha-synuclein reminiscent of oligomers and protofibrils and fibrillar types, which participates in neurodegenerative problems together with Parkinson’s illness. The objective is to develop a illness modifying remedy that stops or decelerate the development of Parkinson’s illness.  

About BioArctic AB

BioArctic AB (publ) is a Swedish research-based biopharma firm specializing in disease-modifying remedies for neurodegenerative ailments, reminiscent of Alzheimer’s illness, Parkinson’s illness and ALS. BioArctic focuses on revolutionary remedies in areas with excessive unmet medical wants. The corporate was based in 2003 based mostly on revolutionary analysis from Uppsala College, Sweden. Collaborations with universities are of nice significance to the corporate along with its strategically vital international companion Eisai in Alzheimer illness. The mission portfolio is a mix of totally funded initiatives run in partnership with international pharmaceutical corporations and revolutionary in-house initiatives with vital market and out-licensing potential. BioArctic’s Class B share is listed on Nasdaq Stockholm Massive Cap (ticker: BIOA B). For extra details about BioArctic, please go to www.bioarctic.com.

This data was dropped at you by Cision http://information.cision.com

https://information.cision.com/bioarctic/r/study-results-from-phase-1-studies-with-exidavnemab-published-in-the-journal-of-clinical-pharmacolog,c4028830

The next recordsdata can be found for obtain: